Surges & Plunges - EVOK, OREX, MRUS, IMGN, AGRX

(RTTNews) - The following are the stocks that made the most gains or harvested some losses on Wednesday (January 4, 2017).

Gainers

1. Stock: Evoke Pharma Inc. (EVOK)

Price movement: Gained 29.95% to close Wednesday's trading at $2.69.

News: Related to phase III trial product candidate Gimoti

Additional data from phase III trial of Gimoti, a metoclopramide nasal spray, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adult women has demonstrated statistically significant benefit at multiple time points. Nausea and abdominal pain symptoms significantly reduced in patients with higher symptom severity.

The topline results from the study were reported on July 18, 2016. The trial did not achieve its primary endpoint of symptom improvement at Week 4.

2. Stock: Orexigen Therapeutics Inc. (OREX)

Price movement: Gained 64.25% to close Wednesday's trading at $3.40.

News: Related to the company's FDA-approved prescription weight-loss medicine Contrave.

A new, national direct-to-consumer advertising campaign titled "Brains Behind Weight Loss" has been launched by the company with the aim of showcasing the attributes and benefits of Contrave.

The campaign is Orexigen's first collaboration with Young & Rubicam New York, and it will span network and cable television, magazines, digital displays, online video, social media and a new website.

3. Stock: Merus NV (MRUS)

Price movement: Gained 22.92% to close Wednesday's trading at $25.90.

News: No News

Near-term catalyst: Report interim results from Part 2 of a Phase 1/2 clinical trial of MCLA-128 in breast cancer in the first quarter of 2017.

4. Stock: CymaBay Therapeutics Inc. (CBAY)

Price movement: Gained 21.05% to close Wednesday's trading at $2.30.

News: Related to a licensing deal with Kowa Pharmaceuticals America Inc. for developing gout drug candidate Arhalofenate in the U.S.

CymaBay will receive up to $15 million in upfront and near-term milestone payments from Kowa. It is also eligible to receive up to an additional $190 million in payments based upon the achievement of specific development, regulatory and sales milestones in addition to royalties on future sales of Arhalofenate products.

5. Stock: ImmunoGen Inc. (IMGN)

Price movement: Gained 19.71% to close Wednesday's trading at $2.49.

News: No news

Anticipated near-term event: Initiation of a phase III trial of mirvetuximab soravtansine monotherapy in platinum-resistant ovarian cancer, dubbed FORWARD I. It was originally scheduled to begin by end of last month.

6. Stock: Seres Therapeutics Inc. (MCRB)

Price movement: Gained 9.79% to close Wednesday's trading at $10.99.

News: No news

Anticipated near-term events: Interim results from Part 2 of a Phase 1/2 clinical trial of MCLA-128 in breast cancer expected to be reported in the first quarter of 2017.

Merus expects to announce the identification of the first Biclonics therapeutic candidate targeting immunomodulation.

7. Stock: CareDx Inc (CDNA)

Price movement: Gained 19.57% to close Wednesday's trading at $2.75.

News: No news

Anticipated near-term event: Q4 and 2016 year-end financial results to be reported in March.

8. Stock: Eleven Biotherapeutics, Inc. (EBIO)

Price movement: Gained 16.08% to close Wednesday's trading at $2.31.

News: No news

Anticipated near-term event: The company's drug candidate Proxinium is expected to enter a Phase 2 clinical trial in combination with a checkpoint inhibitor in the first half of 2017 for the treatment of late-stage squamous cell carcinoma of the head and neck.

EBIO's most-advanced compound is Vicinium. Enrollment in a phase III trial of Vicinium as a potential treatment of high grade non-muscle invasive bladder cancer is expected to be completed in the first half of this year.

9. Stock: Champions Oncology Inc. (CSBR)

Price movement: Gained 13.33% to close Wednesday's trading at $3.23.

News: No news

Anticipated near-term event: Results for Q3 ended January 31, 2017 to be reported in March.

10. Stock: TrovaGene Inc. (TROV)

Price movement: Gained 14.63% to close Wednesday's trading at $2.35.

News: No news

Anticipated event: Multiplexed urine and blood ctDNA liquid biopsy assay kits developed by Trovagene and Boreal Genomics to be launched this year.

11. Stock: Achaogen Inc. (AKAO)

Price movement: Gained 14.46% to close Wednesday's trading at $14.88.

News: No news

Anticipated event: Submit NDA for Plazomicin seeking approval as a treatment for multi-drug resistant (MDR) gram-negative infections in the second half of 2017.

Plunges

1. Stock: Agile Therapeutics Inc. (AGRX)

Price movement: Lost 47.40% to close Wednesday's trading at $2.63.

News: Related to phase III trial of investigational low-dose combined hormonal contraceptive patch Twirla

The results from the phase III trial of Twirla, dubbed SECURE, were positive. The company said that 51.4% of subjects discontinued prematurely from the study. The SECURE study was conducted to address issues raised by the FDA in its 2013 Complete Response Letter to the company.

Agile plans to resubmit the NDA in the first half of 2017.